Curaleaf Initiates Reverse Stock Split for U.S. Uplisting
Curaleaf Holdings Inc., an international provider of consumer cannabis products, announced a 1-for-3 reverse stock split of its subordinate voting shares, set to become effective on or about June 5, 2026. This initiative is a preparatory step for a potential U.S. stock exchange uplisting, a move made in consultation with major U.S. stock exchanges and in anticipation of U.S. medical cannabis rescheduling, as reported by Cannabis Business Times on May 26, 2026.
Details of the Reverse Stock Split
Operational Mechanics and TSX Approval
The board of directors of Curaleaf Holdings Inc. formally approved the proposal to effect a reverse stock split. This action will consolidate every three pre-consolidation subordinate voting shares into one post-consolidation share. The Toronto Stock Exchange (TSX) has granted conditional approval for this share consolidation, which is expected to take effect on or about June 5, 2026. Following this date, the company’s subordinate voting shares will commence trading on the TSX on a post-reverse stock split basis under the existing ticker symbol “CURA.”
The primary objective of the reverse stock split is to reduce the total number of issued and outstanding subordinate voting shares, which is expected to result in an increased trading price per share. Curaleaf currently has 698,728,008 subordinate voting shares outstanding. Assuming no additional shares are issued prior to the split, this action will reduce the total issued and outstanding shares to approximately 232,909,336.
In terms of fractional shares, Curaleaf will not issue them in connection with the reverse stock split. Instead, where the split would otherwise result in a shareholder being entitled to a fractional subordinate voting share, the number of post-reverse stock split shares issued to that holder will be rounded up or down to the nearest whole number.
Registered shareholders will receive a letter of transmittal from the company’s transfer agent, Odyssey Trust Company. These shareholders will be required to submit their certificate(s) or direct registration advice(s) representing pre-reverse stock split subordinate voting shares, along with the completed letter of transmittal, to receive new post-reverse stock split share certificates or direct registration advice. Shareholders who hold their subordinate voting shares through a broker or other intermediary and do not have shares registered in their name will not need to complete this process.
Strategic Rationale and Regulatory Context
Meeting Exchange Criteria and Expanding Investor Base
Curaleaf’s board approved the reverse stock split to ensure the company meets specific share price level criteria established by major U.S. stock exchanges. This preparation is considered critical as ongoing regulatory developments in the U.S. may soon provide an opportunity for the company to uplist to a prominent U.S. exchange. The initiative also aims to ensure the company’s shares trade above limits set by certain retail brokerage firms, thereby broadening institutional investor participation and potentially improving liquidity.
Curaleaf Chairman and CEO Boris Jordan stated that this step is part of the company’s long-term effort to achieve a listing on a major U.S. stock exchange. He noted that the rescheduling of medical cannabis has created a potential pathway toward this goal, positioning Curaleaf to potentially capitalize on future market opportunities.
Anticipating Medical Cannabis Rescheduling and Industry Normalization
Jordan indicated that a hearing on the full rescheduling of cannabis is expected to conclude in July, with U.S. Treasury guidance supporting industry normalization anticipated. These developments are expected to provide greater clarity regarding the regulatory and tax framework for the cannabis industry. Curaleaf anticipates that such changes could significantly improve access to capital, broaden the investor base, and further legitimize cannabis in public markets. The company is positioning itself to move quickly and decisively when these opportunities materialize, aiming to enhance its market standing and investor appeal.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
